Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

satraplatin

Known as: (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum, bis-acetatoamminedichlorocyclohexylamine platinum(IV), platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43) 
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged… Expand
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Antineoplastic AgentsOrganoplatinum Compounds

Narrower (2)

BMS-182751JM 216
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconverison nanoparticles.
Controlling anticancer drug activity and release on demand is very significant in cancer therapy. The photoactivated platinum(IV… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
The status of platinum anticancer drugs in the clinic and in clinical trials.
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
A potent trans-diimine platinum anticancer complex photoactivated by visible light.
Activating platinum with light: An inert platinum(IV) diazido complex trans, trans,trans-[Pt(N3)2(OH)2(py)2] becomes potently… Expand
Highly Cited
2009
Highly Cited
2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial…
PURPOSE This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2008
Review
2008
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Platinum drugs are major chemotherapeutic agents that are used alone or in combination with other systemic agents and/or… Expand
  • figure 1
  • table 1
Highly Cited
2008
Highly Cited
2008
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.
The integrins alpha vbeta3 and alpha vbeta5 and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed… Expand
Review
2007
Review
2007
The resurgence of platinum-based cancer chemotherapy
  • L. Kelland
  • Nature Reviews Cancer
  • 2007
    • Corpus ID: 205468214
The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2005
Highly Cited
2005
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
DNA damage often activates the p53–p21 pathway and causes G1-phase arrest in mammalian cells. Although there is ample evidence… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1997
Highly Cited
1997
ACTIVATION OF C-H BONDS BY METAL COMPLEXES
ion. The oxidative addition mechanism was originally proposed22i because of the lack of a strong rate dependence on polar factors… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Highly Cited
1995
Highly Cited
1995
Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.
Carboxylation of hydroxide coordinated to Pt(1V) by anhydrides, pyrocarbonates, and isocyanates to form the corresponding Pt(1V… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE